<ENAMEX TYPE="PERSON">Bolar Pharmaceutical Co</ENAMEX> under pressure from the Food and <ENAMEX TYPE="ORGANIZATION">Drug Administration</ENAMEX> agreed to recall its generic version of the antibiotic drug <ENAMEX TYPE="LOCATION">Macrodantin</ENAMEX> from retail shelves according to <ENAMEX TYPE="ORGANIZATION">FDA</ENAMEX> officials It was another setback for <ENAMEX TYPE="PERSON">Bolar</ENAMEX> the flagship of the generic drug industry Earlier this month <ENAMEX TYPE="PERSON">Bolar</ENAMEX> began recalling its nitrofurantoin macrocrystalline capsules from wholesalers and distributors because of <ENAMEX TYPE="ORGANIZATION">FDA</ENAMEX> evidence suggesting that the company passed off <ENAMEX TYPE="LOCATION">Macrodantin</ENAMEX> as its own to obtain <ENAMEX TYPE="ORGANIZATION">FDA</ENAMEX> approval to market its generic product At that time however the company balked at a retail recall arguing that the evidence wasn t sufficient to justify such a move But on Oct 25 the <ENAMEX TYPE="ORGANIZATION">FDA</ENAMEX> offered additional evidence to buttress its case that the brand name drug had been substituted for <ENAMEX TYPE="PERSON">Bolar</ENAMEX> s product in pre market testing <ENAMEX TYPE="ORGANIZATION">FDA</ENAMEX> officials said yesterday The agency now has evidence that <ENAMEX TYPE="PERSON">Bolar</ENAMEX> submitted <ENAMEX TYPE="LOCATION">Macrodantin</ENAMEX> as its generic version for testing not only at Pharmakinetics Laboratories <ENAMEX TYPE="LOCATION">Inc Baltimore</ENAMEX> but also at an independent laboratory in <ENAMEX TYPE="LOCATION">Canada FDA</ENAMEX> investigators obtained a sample of the <ENAMEX TYPE="PERSON">Bolar</ENAMEX> drug from the <ENAMEX TYPE="LOCATION">Canadian</ENAMEX> lab according to <ENAMEX TYPE="ORGANIZATION">FDA</ENAMEX> official <ENAMEX TYPE="PERSON">Michael Shaffer</ENAMEX> It turned out to be the brand name product he said In <ENAMEX TYPE="LOCATION">Copiague N Y Robert Shulman</ENAMEX> president of <ENAMEX TYPE="PERSON">Bolar</ENAMEX> and sales director <ENAMEX TYPE="PERSON">Karen Sattig</ENAMEX> couldn t be reached for comment The inspector general s office of the Health and <ENAMEX TYPE="ORGANIZATION">Human Services Department</ENAMEX> already is conducting a criminal investigation of whether <ENAMEX TYPE="PERSON">Bolar</ENAMEX> filed false information with the <ENAMEX TYPE="ORGANIZATION">FDA</ENAMEX> in seeking clearance to market at least two generic drugs Meanwhile the <ENAMEX TYPE="ORGANIZATION">FDA</ENAMEX> is moving to withdraw its approval of <ENAMEX TYPE="PERSON">Bolar</ENAMEX> s nitrofurantoin macrocrystalline capsules which are used primarily to treat urinary tract infections The brand name drug is manufactured by <ENAMEX TYPE="PERSON">Norwich Eaton</ENAMEX> a subsidiary of <ENAMEX TYPE="LOCATION">Cincinnati</ENAMEX> based Procter Gamble Co Although no health problems are known to have been caused by <ENAMEX TYPE="PERSON">Bolar</ENAMEX> s product the <ENAMEX TYPE="ORGANIZATION">FDA</ENAMEX> officials said the agency can no longer ensure that it is the equivalent of <ENAMEX TYPE="LOCATION">Macrodantin</ENAMEX> In <ENAMEX TYPE="ORGANIZATION">American Stock Exchange</ENAMEX> composite trading yesterday <ENAMEX TYPE="PERSON">Bolar</ENAMEX> closed at 14 375 down 50 cents